Glumitide with Liraglutide

The receipt

Evidence on the combination

Human pilots

Knop et al., 2024

What each does alone

• Weight loss · Weekly shotGlumitideGIPLilly's trial-only shot, built from one half of Zepbound. Data: two Phase 1 studies, four weeks of dosing.Human pilotsGray marketChecked Oct 18
• Weight loss · Daily shotLiraglutideGLP-1The daily shot before Ozempic, approved for teenagers from 12. Its main trial: 8% weight loss at 56 weeks.Approved drugFDA approvedChecked Oct 18

Mechanism overlap · reasoning, not evidence

Glumitide

Peptide — Selective GIP Receptor Agonist (Investigational)

Liraglutide

Incretin Peptide — Daily GLP-1 Receptor Agonist

Shared mechanism tag

incretin peptide

Reasoning, not evidence: what each is described to do says nothing about what they do together.

What the studies found

Healthy volunteers, NCT05444569 (Knop et al., 2024)

• What was given — 34 healthy adults enrolled in Singapore and 32 dosed: a single 25 mg injection of LY3537021 (glumitide) or placebo, then liraglutide escalated daily from 0.6 mg to 2.4 mg by day 5 and held to day 9; after 8 weeks, the other arm (open-access full text).
• What it found — Total gastrointestinal adverse events: 41 with LY3537021 vs 75 with placebo (P = .022). The share with any such event was 56% vs 72% (not significant); nausea or vomiting 25% vs 37.5%. All adverse events were mild.
• Limits — Nine days of liraglutide, one dose of glumitide; the authors call the analyses exploratory; funded by Eli Lilly.

No study has tested glumitide with liraglutide for weight loss; this was a nine-day tolerability study.